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Background Atrial fibrillation (AF), whether silent or symptomatic, is a
frequent and severe complication of acute myocardial infarction (AMI).
Asymmetric dimethylarginine (ADMA), an endogenous eNOS inhibitor, is a
risk factor for endothelial dysfunction. We addressed the relationship between
ADMA plasma levels and AF occurrence in AMI.
Methods 273 patients hospitalized for AMI were included. Continuous
electrocardiographic monitoring (CEM) ≥48 hours was recorded and ADMA
was measured by High Performance Liquid Chromatography on admission
blood sample. 
Results The incidence of silent and symptomatic AF was 39(14%) and 29
(11%), respectively. AF patients were markedly older than patients without
AF (≈20y). There was a trend towards higher ADMA levels in patients with
symptomatic AF than in patients with silent AF or no AF (0.53 vs 0.49 and
0.49 μmol/L, respectively). After matching on age, we found that patients with
symptomatic AF had a higher heart rate on admission and a higher rate of
patients with LV dysfunction (28% vs. 3%, p=0.025). Patients who developed
symptomatic AF had a higher ADMA level (0.53 vs. 0.43 μmol/L; p=0.001).
Multivariate logistic regression analysis to estimate symptomatic AF occur-
rence showed that ADMA was independently associated with symptomatic AF
(OR: 2.46 [1.21-5.00], p=0.013) beyond history of AF, LVEF<40% and ele-
vated HR.
Conclusion We show that high ADMA level is associated with the occur-
rence of AF. Although no causative role can be concluded from our observa-
tional study, our work further supports the hypothesis that endothelial
dysfunction is involved in the pathogenesis of AF in AMI. 
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Background CD40 Ligand (CD40L) is expressed on platelets upon ADP
stimulation and is involved in haemostasis. CD40L deficient mice exhibit
thrombus instability and increased bleeding time. 
Methods We investigated the relationships between plasma and platelet-asso-
ciated CD40L, ADP signaling and bleeding event occurrence in patients receiving
thienopyridines one month after a stented Acute Coronary Syndrome (ACS).
Basal platelet CD40L surface expression (pCD40L), pCD40L after PAR-1 agonist
stimulation (TRAP pCD40L) and platelet released CD40L (rCD40L) were quan-
tified. Results were compared to VASP as a measure of P2Y12 inhibition level. 
Results We included 318 patients between November 2012 and June 2014.
Thienopyridines treated patients exhibit low pCD40L, TRAP pCD40L and
rCD40L in comparison with controls. pCD40L and rCD40L were correlated
with PRI-VASP. Thienopyridine treatment strongly reduces rCD40L. Hypere-
sponder to thienopyridine status is associated with high levels of TRAP
pCD40L. pCD40L and TRAP pCD40L levels are reduced in the bleeding
cohort. In multivariate analysis pCD40L significantly contributes to bleeding
risk independently of PRI-VASP.
Conclusion pCD40L and rCD40L levels are reduced by thienopyridines.
pCD40L associates with the bleeding risk independently of the VASP levels
and may represent a novel target to assess bleeding risk in thienopyridine-
treated ACS patients.
The author hereby declares no conflict of interest
0133
The Log Book as a new tool for the secondary prevention of coronary
artery disease 
Elodie Boch (1), Aurélien Vaillant (2), Laura Gay (2), Marie-Charlotte
Moreau (2), Frédérique Germin (2), Philippe Brunel (3), Gilles Morel (3),
Aline Chagnon (4), Yves Cottin (4), Marianne Zeller* (5)
(1) CHU Dijon, Bocage, Dijon, France – (2) Université Bourgogne,
Dijon, France – (3) Clinique Fontaine, Fontaine Les Dijon, France – (4)
CHU Tours, Tours, France – (5) Université de Bourgogne, INSERM
U866, Dijon, France
*Corresponding author: marianne.zeller@u-bourgogne.fr (Marianne Zeller)
Introduction The Log book (LB) project was created by a multidisci-
plinary team of healthcare professionals from a regional care network and
aimed to improve secondary prevention (SP) after acute myocardial infarction
(MI) in Cote d’Or. LB includes information and advices for increasing self
management of risk factors by the patient. 
Methods A prospective interventional study on 469 patients hospitalised
for an acute MI in the 2 Intensive Coronary Care unit of Côte d’Or (CHU
Dijon and Clinique de Fontaine les Dijon) in 2012 and surviving at 1 year
follow-up (FU). LB was randomly given at the time of their hospitalisation by
the nursing team, also providing oral advices on risk factors management and
CV health self care. Patients who received LB (LB+) were compared with
patients without LB (LB-). 
Results Patients from LB+ group (n=307(65%)) were younger (57 vs 63y,
p<0.001)) and less frequently women (16 vs 32%, p<0.001), diabetic (17 vs
30%, p<0.001) or with prior CAD (7 vs 15%, p=0.008) than patients without
LB (LB- group, n=162(35%)). After matching patients LB+ with LB- based
on age, sex, diabetes and GRACE risk score (n=127 in each group), baseline
characteristics, were similar in the 2 groups. At 1 year FU, there was a trend
for more frequent visits to the cardiologist in the LB+ group (2±1 vs 1±1,
p=0.056) and cardiac rehabilitation program was more often performed in
LB+ patients (69 vs 54%, p=0.015). Moreover, weight loss in obese patients
and smoke withdrawal rates also showed a trend for improvement in LB+
patients (respectively 71 vs 59%, p=0.311 and 69 vs 53%, p=0.109). Finally,
patients with LB showed a trend toward a lower rate of combined outcomes
including recurrent MI, hospitalisation for heart failure and unscheduled PCI
than in the LB- group (3 vs 7%, p=0.155). 
Conclusion These preliminary data of our ongoing regional study suggest
the efficacy of LB as a support for CV risk factor self management. In addi-
tion, our study provides encouraging data on the potential clinical benefits of
this pioneer tool for SP.
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Introduction in animal models of atheroma (ApoE-/- and LDL -/- mice),
bile acids (BAs) exerts an anti-atherosclerotic effect through the anti-inflam-
matory action of their receptors, TGR5 and FXR, decreasing dramatically the
surface of the atheroma plaque. BAs are cholesterol derivatives synthetized by
the liver. In a previous study, we found that a decrease in BAs (lithocholic
acid) is an independent risk factor of coronary disease in human.
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Aim Statins are known to reduce cardiovascular events in atherosclerotic
patients. Given the experimental protective effect of BAs against atheroscle-
rosis, the aim of this preliminary study was to dertermine the total BAs con-
centration in sera after statins administration. 
Methods Between January 2015 and April 2015, patients hospitalized for a
coronary angiogram and starting a statins treatment for coronary atheroma were
included. Exclusion criteria were post cardiac arrest, non-fasting status, hepatic
disease, antibiotics and corticosteroids. The total BAs concentration was mea-
sured before and 1 month after the initiation of statin therapy by liquid chroma-
rography mass spectrometry. Wilcoxon test was used for statistical analysis. 
Results On a cohort of 360 patients, 37 were eligible and 17, aged of
54±9.6 years old have been retrospectively included. 95% were prescribed
with atorvastatin (68% with atorvastatin 40mg). The mean concentration of
the total BAs before statin was 0.68μmol/L (SEM 0.08μmol/L) and 1.37μmol/
L after (SEM 0.21μmol/L) (p=0.013, figure 1). 
Conclusion statins administration is associated with a doubling of circu-
lating BAs after one month of treatment. This raises a question about statins
increasing BAs synthesis by the liver: the deflection of the cholesterol synthesis
by the liver into BAs instead, could participate to the efficacy of statins. This
could theoretically be beneficial by slowing down the atheroma development
through anti-inflammatory effects of BAs on the macrophage of the plaque.
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Background Despite dual antiplatelet treatment with the new P2Y12
platelet receptor antagonists (P2Y12i), major ischemic events are common fol-
lowing ST elevation myocardial infarction (STEMI). 
Objectives To assess separately resistance to aspirin (HPR-aspirin), resis-
tance to P2Y12i (HPR-P2Y12i) and their association during the acute phase
of STEMI in relation to the occurrence of ischemic events.
Methods We included all consecutive patients admitted for STEMI in our
center between January 2013 and December 2013. All patients received a
loading dose followed by a maintenance dose of aspirin (75mg/day) and either
clopidogrel, prasugrel or ticagrelor. Platelet reactivity was assessed 4±1 days
and 75±15 days after admission using light transmission aggregometry (LTA)
with arachidonic acid (AA) and serum Thromboxane-B2 concentration to
assess HPR-aspirin and LTA-ADP and VASP index to assess HPR-P2Y12i.
Major cardiac and cerebrovascular events (MACCE) were recorded during
one year.
Results 106 patients (61years old, 76% male, 20% with diabetes) were
included. STEMI was anterior in 52% and LV ejection fraction at discharge
was 51±9%. At day 4 after STEMI, HPR-aspirin measured by LTA-AA alone
was found in 23% patients and was correlated with serum thromboxane inhi-
bition, HPR-P2Y12i (VASP≥50% and LTA-ADP≥65%) was observed only in
7% and combined resistance was present in 4% of the patients. Diabetes and
age were predictors of HPR-aspirin. The large use of ticagrelor (34%) and pra-
sugrel (50%) explained the low rate of P2Y12i resistance. HPR-aspirin was
persistent 75 days later in 36% patients who were resistance at day 4. At
1 year, 7.9% patients had experienced MACCE. HPR-aspirin alone and HPR
for both aspirin and P2Y12i were significantly associated with MACCE.
Conclusion Aspirin resistance is frequent just after STEMI and is associ-
ated with MACCE especially when associated with P2Y12i resistance.
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Aim To document low-density lipoprotein cholesterol (LDL-C) values
during hospitalization of ACS patients with/without lipid-lowering therapy
(LLT) at admission, and achievement of the ESC LDL-C target (LDL-C
≤70mg/dL) at 4 months following the acute event using data from the French
cohort of the DYSIS IIACS study.
Methods DYSIS IIACS was a multicentre prospective observational cohort
study (recruitment: Oct 2013 to Oct 2014) conducted in 24 coronary care units
in France. Adults hospitalized for an ACS event and who had a lipid panel
measured within 24 hours of admission were consecutively enrolled. Eligible
patients had to be on LLT for ≥3 months or taking no LLT. A telephone
follow-up interview was carried out with patients (or their next of kin) 120±15
days after the index event.
Results Of the 468 patients enrolled, 50.6% had ST-elevation myocardial
infarction/left bundle branch block, 40.8% had non-ST-elevation myocardial
infarction, and 8.5% had unstable angina. Of the 277 (59.2%) patients on LLT
at admission, 25.3% had an LDL-C <70mg/dl (Table). Most patients (96.4%)
were on statin therapy at discharge (mean+SD dose calculated in atorvastatin
49±28mg/day). Non-statin LLT was used in 5.6% patients at discharge (61.5%
with a cholesterol-absorption inhibitor). At 120 days after admission, 50.9%
of ACS patients with follow-up data had achieved the LDL-C target.
Conclusions These observational data from contemporary French clinical
practice in coronary care units indicate suboptimal LDL-C control, with a sub-
stantial proportion of very high cardiovascular risk patients presenting with
elevated LDL-C despite taking LLT. Four months after the acute event, half
of the patients (with data) failed to achieve the target, with a large difference
between mean value and target LDL-C. 
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